Welcome to
Sysmex Flow Cytometry Other European Country!

For ordering please make sure you are in your local shop.
If you are from Other European Country then please continue.
Otherwise please go to your country.

Go to my country Continue

Article successfully added.

CyFlow™ CD55 FITC

CyFlow™ CD55 FITC
Antigen: CD55
Alternative Name: DAF
Clone: MEM-118
Application: Flow cytometry
Format/Fluorochrome: FITC
Laser: Blue
Target Species: Human, Non-Human Primates
Field of Interest: Immunophenotyping
Species of Origin: Mouse
Regulatory Status: RUO
Clonality: monoclonal
Emission Maximum: 518 nm
Excitation Maximum: 490 to 495 nm
Isotype: IgM
Order number: AG120134

For Research Use Only
Not for use in diagnostic or therapeutic procedures.

HLDA Workshop HLDA V—WS Code AS S016 Quantity 100 tests Volume 2 Immunogen Human... more
CyFlow™ CD55 FITC
HLDA WorkshopHLDA V—WS Code AS S016
Quantity100 tests
ImmunogenHuman Acute Lymphocytic Leukemia (ALL) T cells
Background InformationCD55 (DAF; decay-accelerating factor) is a GPI-anchored membrane glycoprotein that protects autologous cells from classical and alternative pathway of complement cascade. Bidirectional interactions between CD55 and CD97 are involved in T cell regulation and CD55 can still regulate complement when bound to CD97. In tumors, besides protection agains complement, CD55 promotes neoangiogenesis, tumorigenesis, invasiveness and evasion of apoptosis.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 20·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (2 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing Tris buffered saline (TBS) solution, pH ≈8.0, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Doussis IA, Gatter KC, Mason DY: CD68 reactivity of non‑macrophage derived tumours in cytological specimens. J·Clin·Pathol. 1993·Apr; 46(4):334‑6. <·PMID:·7684403·> | Angelisová P, Drbal K, Horejsí V, Cerný J: Association of CD10/neutral endopeptidase 24.11 with membrane microdomains rich in glycosylphosphatidylinositol‑anchored proteins and Lyn kinase. Blood. 1999·Feb·15; 93(4):1437‑9. <·PMID:·10075459·> | Miwa T, Maldonado MA, Zhou L, Sun X, Luo HY, Cai D, Werth VP, Madaio MP, Eisenberg RA, Song WC: Deletion of decay‑accelerating factor (CD55 exacerbates autoimmune disease development in MRL/lpr mice. Am·J·Pathol. 2002·Sep; 161(3):1077‑86. <·PMID:·12213736·> | Mikesch JH, Buerger H, Simon R, Brandt B: Decay‑accelerating factor (CD55): a versatile acting molecule in human malignancies. Biochim·Biophys·Acta. 2006·Aug; 1766(1):42‑52. <·PMID:·16784816·> | Miwa T, Maldonado MA, Zhou L, Yamada K, Gilkeson GS, Eisenberg RA, Song WC: Decay‑accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement‑dependent and ‑independent mechanisms. Am·J·Pathol. 2007·Apr; 170(4):1258‑66. <·PMID:·17392165·> | Abbott RJ, Spendlove I, Roversi P, Fitzgibbon H, Knott V, Teriete P, McDonnell JM, Handford PA, Lea SM: Structural and functional characterization of a novel T cell receptor co‑regulatory protein complex, CD97‑CD55. J·Biol·Chem. 2007·Jul·27; 282(30):22023‑32. <·PMID:·17449467·> | VanLandingham JW, Cekic M, Cutler S, Hoffman SW, Stein DG: Neurosteroids reduce inflammation after TBI through CD55 induction. Neurosci·Lett. 2007·Sep·25; 425(2):94‑8. <·PMID:·17826908·>